Találati lista | Tudóstér

001-es BibID:	BIBFORM116529
035-os BibID:	(scopus)85169932064 (wos)001060259500001
Első szerző:	Kendall Bártů, Michaela
Cím:	HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma / Kendall Bártu Michaela, Nemejcová Kristyna, Michálková Romana, Struzinská Ivana, Hájková Nikola, Hojny Jan, Krkavcová Eva, Laco Jan, Matej Radoslav, Drozenová Jana, Méhes Gábor, Fabian Pavel, Hausnerová Jitka, Svajdler Marián, Skapa Petr, Cibula David, Zima Tomás, Dundr Pavel
Dátum:	2023
ISSN:	0945-6317
Megjegyzések:	Ovarian clear cell carcinoma (OCCC) is a subtype of ovarian carcinoma characterized by unique biological features and highly malignant characteristics including low chemosensitivity. Therefore, new therapeutic targets are needed. These could include the downstream pathways of receptor tyrosine kinases, especially the human epidermal growth factor receptor 2 (HER2). Our main objective was to characterize the HER2 status using immunohistochemistry (IHC) and FISH on 118 OCCCs, also considering the novel paradigm of HER2-zero and HER2-low status. Other aims included determination of the association between HER2 status and survival, HER2 gene DNA and RNA NGS analysis, HER2 gene expression analysis, and correlation between IHC and gene expression in HER2-zero and HER2-low cases. Cases with HER2 overexpression/amplification accounted for 5.1% (6/118), with additional 3% harbouring HER2 gene mutation. The remaining 112 (94.9%) cases were HER2-negative. Of these, 75% were classified as HER2-zero and 25% as HER2-low. This percentage of HER2 aberrations is significant concerning their possible therapeutic influence. Cases from the HER2-zero group showed significantly better survival. Although this relationship lost statistical significance in multivariate analysis, the results have potential therapeutic significance. HER2 gene expression analysis showed a significant correlation with HER2 IHC status in the entire cohort (HER2-positive vs. HER2-negative), while in the cohort of only HER2-negative cases, the results did not reach statistical significance, suggesting that gene expression analysis would not be suitable to confirm the subdivision into HER2-low and HER2-zero. Our results also emphasize the need for standardized HER2 testing in OCCC to determine the best predictor of clinical response.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk HER2 Ovarian clear cell carcinoma Immunohistochemistry Gynecopathology Ovarian cancer
Megjelenés:	Virchows Archiv. - 483 : 4 (2023), p. 497-507. -
További szerzők:	Nĕmejcová, Kristýna Michálková, Romana Struzinská, Ivana Hájková, Nikola Hojny, Jan Krkavcová, Eva Laco, Jan Matej, Radoslav Drozenová, Jana Méhes Gábor (1966-) (patológus) Fabian, Pavel Hausnerová, Jitka Svajdler, Marián Škapa, Petr Cibula, David Zima Tomás Dundr, Pavel
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: